A Phase II,Single-arm,Multicenter Study of Radiotherapy Followed by Chemotherapy Combined With Toripalimab Immunotherapy in Locally Advanced HR-positive,HER2-negative Breast Cancer
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- 29 Nov 2024 New trial record